
    
      This is an extension treatment protocol to allow access to tivozanib or sorafenib for
      subjects enrolled on AV-951-09-301(parent protocol). Subjects who failed sorafenib on the
      parent protocol will be offered tivozanib. Subjects who were randomized to tivozanib, and
      demonstrated clinical benefit and acceptable tolerability will be offered long-term access to
      tivozanib. Subjects who were randomized to sorafenib, and demonstrated clinical benefit and
      acceptable tolerability will be offered long-term access to sorafenib. Subjects who continue
      receiving sorafenib on this protocol and progress will be allowed to cross-over to tivozanib.
    
  